The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Open accessAbstract
Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Self-citationApplication of a Theory of Enzyme Specificity to Protein Synthesis
Koshland, D. E. (1958) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.44.2.98 · Cited by 2,396
Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476
Self-citationX-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467
Self-citationMechanisms of caspase activation
Boatright, K. M., & Salvesen, G. S. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.009 · Cited by 1,377
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Green, D. R., & Evan, G. I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00024-7 · Cited by 1,254
Nuñez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., & Korsmeyer, S. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3602 · Cited by 899
Cited by
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Self-citationReaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727
Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709443104 · Cited by 659
BCL-2 family antagonists for cancer therapy
Lessene, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 621
Recent advances in the trifluoromethylation methodology and new CF3-containing drugs
Zhu, W., Wang, J., Wang, S., Gu, Z., Aceña, J. L., Izawa, K., Liu, H., & Soloshonok, V. A. (2014) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2014.06.026 · Cited by 493
Drug discovery beyond the ‘rule-of-five’
Zhang, M.-Q., & Wilkinson, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.005 · Cited by 418
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Self-citationVerdine, G. L., & Walensky, L. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2184 · Cited by 361
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Vogler, M., Dinsdale, D., Dyer, M. J. S., & Cohen, G. M. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.137 · Cited by 357
Bcl-2 proteins and mitochondria—Specificity in membrane targeting for death
Lindsay, J., Esposti, M. D., & Gilmore, A. P. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.10.017 · Cited by 346
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Self-citationSmith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300346w · Cited by 278
Lee, E. F., Czabotar, P. E., Smith, B. J., Deshayes, K., Zobel, K., Colman, P. M., & Fairlie, W. D. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402178 · Cited by 278
Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future
Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 260
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Birkinshaw, R. W., Gong, J.-N., Luo, C. S., Lio, D., White, C. A., Anderson, M. A., Blombery, P., Lessene, G., Majewski, I. J., Thijssen, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10363-1 · Cited by 254
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Systematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors
Jochim, A. L., & Arora, P. S. (2010) · ACS Chemical Biology · doi:10.1021/cb1001747 · Cited by 191
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Modulating Protein–Protein Interactions with Small Molecules: The Importance of Binding Hotspots
Thangudu, R. R., Bryant, S. H., Panchenko, A. R., & Madej, T. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.026 · Cited by 71
Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
Pandey, V., Wang, B., Mohan, C. D., Raquib, A. R., Rangappa, S., Srinivasa, V., Fuchs, J. E., Girish, K. S., Zhu, T., Bender, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804897115 · Cited by 59
Metadata
- Authors
- Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., Nimmer, P. M., Oltersdorf, T., Park, C.-M., Petros, A. M., Shoemaker, A. R., Song, X., Wang, X., Wendt, M. D., Zhang, H., Fesik, S. W., Rosenberg, S. H., & Elmore, S. W.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-01-26
- Volume
- 50
- Issue
- 4
- Pages
- 641-662
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2158467294
- Cited by
- 304
- References
- 23
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.